Human apolipoprotein a 1 quantikine elisa kit

In the validation phase, we used a separate cohort of 72 volunteers (MM = 36, control = 36) to perform ELISA based validation in serum samples. All the ELISA experiments were performed according to the manufacturer’s instructions. We validated a panel of five proteins with the Human Haptoglobin Quantikine ELISA kit (catalog #DHAPG0; R&D Systems, Inc., Minneapolis, USA), Human Kininogen DuoSet ELISA kit (catalog #DY1569-05; R&D Systems, Inc., Minneapolis, USA), Human Apolipoprotein A-I Quantikine ELISA Kit (catalog #DAPA10; R&D Systems, Inc., Minneapolis, USA), Human sTfR Quantikine IVD ELISA Kit (1 Kit) (catalog #DTFR1; R&D Systems, Inc., Minneapolis, USA), Human Serum Albumin DuoSet ELISA, 15 Plate (1 KIT) (catalog #DY1455; R&D Systems, Inc., Minneapolis, USA). The optical density of the each sample was determined by using an EPOCH 2 microplate reader (Biotek, USA) set to 450 nm and 570 nm. Optical imperfections correction was done by subtracting the readings of 570 nm from 450 nm readings. Further quantitative analysis was performed using GraphPad Prism software.

APOA1, APOB and CD9 quantification were performed using the Human Apolipoprotein A‐I Quantikine ELISA Kit (DAPA10, R&D Systems, Minneapolis, USA), Apolipoprotein B (APOB) Human SimpleStep ELISA Kit (ab190806, Abcam, Cambridge, UK) and the TRIFic CD9 exosome assay (EX101, Cell Guidance Systems, Carlsbad, California, USA) according to the manufacturer's protocol respectively. Data measurements were obtained using the BioTek Synergy HTX S1LFA and Gen5 software (BioSPX, Drogenbos, Belgium) and the Paradigm Detection Platform (Beckman Coulter, Fullerton, California, USA) and SoftMax Pro 6.1 software (Molecular Devices, Sunnyvale, California, USA).